Kyowa Kirin Head Sees Major Global Status For Newly Formed Biotech
This article was originally published in PharmAsia News
Executive Summary
Kyowa Kirin intends to go head to head in 2012 with the world's largest biotechnology companies, the president of the recently formed Japanese company says. Created through a merger of Kyowa Hakko Kogyo and Kirin Pharma last October, the company is banking on its advanced antibody technologies to help it catch up with big biotechs such as Amgen and Genentech of the United States. The key technologies in that effort are Potelligent and Complegent, already licensed to 10 drug makers, including major multinationals. Kyowa Kirin President Yuzuru Matsuda anticipates blockbuster status for drugs derived from the technologies, which would lead to a "rain fall" of royalties for the company. (Click here for more - a subscription may be required
You may also be interested in...
Kyowa Hakko Kirin Licenses Anti-LIGHT MAB To Sanofi-Aventis
TOKYO - Kyowa Hakko Kirin signed a licensing agreement with Sanofi-Aventis for worldwide co-development and marketing rights, excluding Japan and Asia, for Kyowa's anti-LIGHT fully humanized monoclonal antibody, the company said May 14
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.